India, Jan. 21 -- MAIA Biotechnology, Inc. (MAIA), a clinical-stage immuno-oncology company, provided 2025 corporate highlights, including Ateganosine, MAIA's lead drug for non-small cell lung cancer, and outlined key targeted milestones and growth catalysts for 2026.
Published by HT Digital Content Services with permission from RTT News....